Russian scientists at the Vector Center have successfully finished clinical trials for NIOKH-14, a new antiviral drug to treat monkeypox. Alexander Agafonov, the center head, announced that after analyzing various molecules, they developed an effective formula for a drug in capsule form.
“We went through many molecules that could have antiviral activity. We found it, passed it on to specialists who made a dosage form in the form of a capsule. And now this drug has also passed clinical trials, has shown harmlessness and is ready for use,” he said.
The test results confirmed the safety of the drug and its readiness for use. The drug works by blocking virus reproduction in the body and has been proven effective against both monkeypox and cowpox. The therapeutic course lasts six days.
